White blood cell disorders:
Indications for NYVEPRIA:
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use:
Not for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Adults and Children:
See full labeling. ≥45kg: Do not give between 14 days before and 24 hours after chemotherapy. 6mg SC once per chemotherapy cycle. Children (<10kg): 0.1mg/kg; (10–20kg): 1.5mg; (21–30kg): 2.5mg; (31–44kg): 4mg. Direct administration of prefilled syringe with doses <6mg is not recommended.
Monitor for splenomegaly, splenic rupture, acute respiratory distress syndrome (ARDS); evaluate if fever, lung infiltrates, or respiratory distress occurs; discontinue if ARDS diagnosed. Permanently discontinue if serious allergic reactions develop. Sickle cell disorders; discontinue if sickle cell crisis occurs. Monitor for glomerulonephritis; consider dose reduction or interruption if treatment-related. Monitor CBC during therapy. Discontinue if aortitis is suspected. Myeloid malignancies. Myelodysplasia. Possible transient (+) bone imaging changes in nuclear imaging. Pregnancy. Nursing mothers.
Granulocyte colony stimulating factor.
Bone or extremity pain; anaphylaxis, ARDS, splenic rupture, glomerulonephritis, leukocytosis, aortitis, capillary leak syndrome (monitor closely if occurs).
Generic Drug Availability:
Single-dose prefilled syringe—1 (w. supplies)